Summary The effects of interferon-a (IFN) plus tamoxifen (TMX) 
Patients with advanced or metastatic breast cancer continue to pose major therapeutic dilemmas for the practising oncologist. Despite advances in the detection and treatment of early stage disease, patients with advanced breast cancer almost invariably die of the illness despite fairly frequent responses to various treatment modalities (Henderson, 1987) . Additions to and substitutions of one or other chemotherapeutic agent/s in conventional dose combination chemotherapy has moreover failed to produce any further substantial improvement in either response rate or response duration (Coates et al., 1987) .
Since the aim of treatment for patients with metastatic disease is palliative, an important consideration is therapy related toxicity. Amongst the palliative therapies, there is no doubt that hormonal manipulation remains the approach with the least treatment related morbidity and mortality. Hormonally based treatment is however limited both as to the proportion of patients responding and the duration of response (Byer et al., 1979; Powles et al., 1984; . While a number of new hormonal agents have become available over the last few years it seems unlikely that there will be major differences among any of them in regard to either of these limitations. It would seem reasonable however to explore approaches which might increase the effectiveness of hormone based treatment from either the response rate or response duration point of view.
Although interferon appears to have limited clinical effect as a single agent it has interesting in vitro effects on various breast cancer derived, estrogen responsive, cell lines including MCF7 and ZR 75 cells. Alpha interferon has been shown to increase estrogen receptor (ER) expression, and to have a synergistic effect together with tamoxifen (TMX) in inhibiting MCF-7 cell growth (Bezwoda & Meyer, 1990 ). Other authors have reported similar effects with a interferon using the ZR 75 cell line (Van den Berg et al., 1987) and with P-interferon using other breast cancer derived cell lines (Sica et al., 1987) .
In view of the potentially favourable effects of alphainterferon on both ER expression and response to tamoxifen we performed a small pilot trial utilising interferon with tamoxifen in patients with locally advanced metastatic breast cancer. This study gave the opportunity to examine the effects of these agents on in vivo tumour biology.
Methods
Premenopausal and postmenopausal patients were considered eligible for entry to the trial if they had informed consent, had evaluable disease, metastatic skin or soft tissue lesions suitable for biopsy, had failed conventional cytotoxic chemotherapy, and had no prior exposure to hormonal manipulation. Recruitment began in June 1990 and ended 12 months later.
All patients underwent initial biopsy by means of a dermatological punch biopsy or cytologic examination by fine needle aspiration and were then started on interferon-x 2b (Intron A -Scherag S.A.; IFNa) 3 million units subcutaneously three times per week. Fourteen days later patients underwent a second biopsy, and tamoxifen 20mg per day by mouth was added to the treatment. Fourteen days later a third biopsy was performed.
Response was assessed on the basis of criteria proposed by the Eastern Co-operative Oncology Group (Hayward et al., 1979 (Seymour et al., 1990a; Seymour et al., 1990b; Seymour et al., 1990c Table I .
Four of the seven patients (57%) responded, of which one (14%) was a complete response. Two of the four responders had early minor responses to IFN prior to addition of TMX to the treatment regimen. The response duration ranged from 4 weeks to 32 weeks. Three patients had no initial response to therapy. Toxicity from IFN was minimal at the doses used (Table II) . Flu-like symptoms and fever when they occurred were readily controlled with the use of paracetamol. At baseline evaluation 5/7 patients were ER positive and four were PR positive as well. All of the responses occurred among the ER positive patients, although one patient who was both ER and PR positive failed to respond. All of the ER positive patients, including the non-responder, showed an increase in the intensity of ER staining after IFNa. Of the three responders who were PR positive, one increased, one decreased and one showed no change in PR expression after interferon, but all increased PR expression after TMX (Table   III ).
All of the responding patients were also initially P24 positive and all showed an increase in P24 immunostaining after interferon administration. Two of the non-responders showed positive immunostaining for P24 prior to IFN therapy, and both became negative after IFN.
Two of the four responders had elevated Ki 67 levels (18-25%), which decreased to low levels after the initiation of IFNa therapy. Of the three non-responders, only one had an elevated Ki 67 (19%), which failed to decrease after either interferon or tamoxifen. This patients was both ER and P24 negative.
Although immunostaining for TGF,8 could be demonstrated in all patients, levels in ER positive patients were higher (mean 2,7) than those in ER negative patients (mean 1,5). Of the four responders, three had no change and one decreased the degree of staining. All the non-responders decreased TGFP levels after interferon and or tamoxifen (Table IV) .
All of the patients showed positive staining for PDGF aa, but there was no clear pattern of change after either interferon or tamoxifen that was correlated with response. Only two patients had clear positive immunostaining for PDGF bb, and both of these were responders (IPR, 1CR). Responding patients thus had a significantly higher level of PDGF bb than non-responders (1,02 vs 0,2) (Table IV) .
When all the variables were examined for an association with response to treatment only pretreatment ER positivity and an increase in P24 expression after IFN treatment correlated significantly with response (Table V) .
Discussion
In vitro studies suggest that the interferons should be useful in the treatment of breast cancer, modulating both tumour The alterations induced by IFN pretreatment on the expression of the proliferation associated antigen Ki 67, which has previously been shown to correlate with mitotic index, 'S' phase fraction and prognosis in breast cancer (Barnard et al., 1987; Walker & Camplejohn, 1988) , were those which were predicted from the in vitro anti-proliferative effects of IFN. Both the patients who had initial high Ki 67 expression, showed significant reduction after IFN and both responded to therapy.
The in vivo demonstration of PDGF in breast cancer cells was also of some interest. The presence of both PDGF and its receptor in a number of soft tissue tumours suggest that PDGF may have an auto-stimulatory role in the growth of these cancers (Perosio & Brooks, 1989) . PDGF occurs in three isoforms. While the bb isoform has the most mitogenic activity, the aa isoform is most commonly observed in tumours. We have previously demonstrated that increased plasma levels of PDGF are of prognostic importance in breast cancer, and that elevated levels correlate with tumour bulk (Ariad et al., 1991) . PDGF aa staining was found to be positive prior to treatment in the majority of breast cancers studied in this investigation, although no correlation could be found between level of expression and any other variable, including response to treatment in this small study. PDGF bb, however, was positive in only 2/7 patients, both of whom were ER positive and both of whom responded to therapy. Neither patient showed any significant change in PDGF bb immunostaining after IFN or IFN and TMX. Although PDGF has previously been detected in breast cancer cell lines (Perosio & Brooks, 1989) , the present study appears to be the first in which PDGF has been demonstrated in clinical breast cancer specimens.
The in vivo pattern of TGFI3 expression was the most difficult to reconcile with the predictions from the in vitro models. TGFP has been extensively studied using the hormonally responsive MCF-7 cell line as a mode. In the MCF 7 model TMX has been shown to induce both the synthesis as well as secretion of TGFi, which then acts as an autocrine growth inhibitor. Although TGFP has mostly been characterised as an inhibitory growth factor (Knabbe et al., 1987; Arrick et al., 1990) , there is evidence which suggests that TGFP may also be growth stimulatory to cells derived from mammary epithelium (Welch et al., 1990) . It should also be pointed out that the majority of patients investigated here showed easily detectable TGFP immunostaining prior to treatment. The question thus arises as to why tumours which demonstrated the presence of an apparently inhibitory growth factor (TGFIB) have such aggressive and clinically progressive disease, as had the patients in this study. While it is possible that functionally active TGF,B levels may not correlate with TGF-beta immunostaining [since TGF,B has been shown to exist in a precursor form (Wakefield et al., 1989) , and the mere presence of TGFI3 immunostaining in cells does not necessarily indicate the presence of active or secretable growth factor], it should be pointed out that the antibody used for dection of TGFPi has neutralising activity and that in our hands, changes in TGF,B immmunostaining have correlated with the expected increase in synthesis and secretion of TGFP in MCF 7 cells following treatment with TMX. It is thus believed that an active form of TGF,B is being detected although, because of cross reactivity were unable to distinguish between the TGFPI3, and TGFI32
isoforms. While the changes in TGFP immunostaining following treatment were variable (Table IV) , it might be pointed out that the non-responders all decreased staining after IFN and/or TMX.
It would appear that for both TGFP and for PDGF, the relationship between the presence of growth factor in tumour cells and the influence on tumour growth is probably more complex than has been appreciated from in vitro studies. The possibility of multiple interactions between malignant cells and stromal cells which can both respond to, and in turn produce their own growth controlling signals (many of which are probably as yet unidentified) makes it probable that the end result is a balance between multiple interactions.
From the clinical point of view, it is difficult to draw conclusions regarding the effectiveness of the combination of IFN plus tamoxifen as compared to tamoxifen alone. The prime object of this pilot study was to determine the in vivo tumour biologic changes resulting from exposure to each of the drugs. In this regard, while the present study confirmed the relationship between ER expression and response to therapy , it should be pointed out that responses in 4/7 (57%) occurring in a group of premenopausal, heavily pretreated patients may well be higher than expected except among a strongly ER positive group, and that IFN did significantly increase ER concentration. Against this, however, is a previous study by Macheldt and co-workers (1991) using a combination of IFN and TMX (either from the outset or by adding IFN to patients not responding to TMX) which came to the conclusion that IFN neither contributed to the response rate observed nor was it able to reverse established TMX resistance. While this question remains unresolved the results of the present study show that IFN (under appropriate conditions) is able to induce in vivo changes in breast tumour determinants which would be expected to result in a synergistic effect with tamoxifen. Moreover, while previous in vitro studies showed that the effects of IFN on ER content were induced fairly rapidly, the present in vivo study demonstrates a sustained effect (lasting for at least 2 weeks) on the increment of ER expression.
Since the present study also showed that some of the effects of TMX and IFN on tumour cells appeared to be opposed (with the addition of TMX causing a downregulation of both ER and P24) the results may also indicate that any therapeutic plan aimed at modulation of biologic influence on tumour cell growth may well have to be approached more subtly than mere empiric combination of the two agents. The optimum method of combining the two therapies may well be by the use of alternating periods of treatment. Such an approach might help to extend the period of hormonal responsiveness amongst patients whose tumours are potentially responsive to tamoxifen through the ER related mechanism of action.
In addition the present study appears to indicate a complex relationship between response to treatment and changes in growth factor expression, which were variably influenced by both interferon and by tamoxifen again with sometimes opposing effects. These studies should caution against a simplistic model of control of tumour cell proliferation derived from a single in vitro model and indicate the need for further research. While such studies may well be complex, the fact that a number of predictions made from in vitro models have been able to be tested and confirmed in vivo, points to the importance of this type of investigation and should provide a stimulus for further research.
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